A platform for quickly creating and testing antibodies
Official title: Platform for the High Throughput Generation and Validation of Affinity Reagents
Funded at Abbratech, INC. · NIH-10769854 · Data updated 2026-11-12
This study is working on a new way to quickly create and test special proteins called antibodies that can help treat diseases, so patients can get better treatments faster and more effectively.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abbratech, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project start | February 1, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,080,240 |
| NIH project number | 5R44GM148998-02 |
| Project ID | NIH-10769854 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who may benefit from monoclonal antibody therapies for their medical conditions.
✕Less likely to help
Patients who do not require monoclonal antibody treatments or have conditions unrelated to antibody therapies may not receive benefits from this research.
What this research studies
This research focuses on developing a comprehensive platform that enables the rapid generation and validation of recombinant monoclonal antibodies (mAbs). It utilizes innovative technologies such as the pATHENA vector system for fast conversion of antibody clones into functional molecules, and the Epivolve method for isolating specific antibodies. The platform also incorporates yeast display for measuring binding affinities and includes automated processes for high-throughput production. Patients may benefit from improved antibody therapies that are developed more efficiently through this advanced methodology.
Why it matters
Potential benefit: If successful, this research could lead to faster and more effective antibody treatments for various diseases.
How similar studies have gone: Other research has shown success in developing antibody platforms, but this specific integration of technologies is relatively novel.
Where this research is happening
-
Abbratech, INC.
Branford, United States Active
Researchers
- Principal investigator: Weiner, Michael P — Abbratech, INC.
- Study coordinator: Weiner, Michael P
Related research
Other NIH-funded projects on the same topics.
-
Antibody Platform for Protein Isoform Splice-Junctions
A fast-track NIH grant aims to create antibodies that specifically recognize unique splice-junctions in proteins, helping to better understand and treat diseases linked to alternative splicing.
-
Creating special antibodies to find disease-related protein changes
This project aims to create new tools, called antibodies, that can find specific changes in proteins linked to various diseases, including cancer.
-
Developing antibodies to fight COVID-19 using advanced technology
This study is working on developing special antibodies that can fight the COVID-19 virus, using a new method to make sure they can keep up with any changes the virus might make, which could help improve treatments for COVID-19 and other infections.
-
Developing antibodies to target specific cancer mutations
This study is working on new antibodies that can help the immune system better recognize and attack cancer cells with a specific KRAS mutation, aiming to make treatments more effective and safer for patients with these types of cancers.
-
Developing antibodies to target specific protein splice variants
This study is working on a new way to find and test special antibodies that can help us understand and treat diseases like cancer by focusing on how proteins are made in different forms, which can change how they behave in the body.
-
Validating antibodies for detecting modified proteins
This study is working to make sure that the tools scientists use to find certain proteins in the lab are more accurate and reliable, which will help improve research and treatments for patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.